Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Tackles Antibiotic Resistance In New UK Guidance

Executive Summary

New final guidance from NICE explains how best to avoid the risk of antibiotic resistance in patients with community- and hospital-acquired pneumonia.

You may also be interested in...



Gedea Champions Both Women’s Health And The Fight Against Antibiotic Resistance

Gedea Biotech is developing an antibiotic-free drug which could significantly improve the treatment of bacterial vaginosis. In Vivo spoke with CEO Annette Säfholm, a 2021 Rising Leader. 

EMA: Multiple COVID-19 Booster Programs ‘Not Sustainable’ In Long Term

Global regulators have been discussing how best to approach vaccination in the face of possible future coronavirus variants, and whether bivalent or multivalent vaccines could be the answer.

EU Extends Provisions For Ensuring Post-Brexit Flow Of Medicines

Proposals for averting medicines supply disruptions caused by Brexit in Northern Ireland and three EU markets are about to be discussed by EU legislators.

Topics

UsernamePublicRestriction

Register

PS140849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel